医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Korean AI-based Diagnostic Software Dr. Answer Helps Countries With a Shortage of Medical Professionals

2021年04月20日 PM09:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Dr. Answer, an innovative artificial intelligence (AI) based diagnostics application, is expected to significantly help countries with insufficient healthcare professionals make more efficient diagnosis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005568/en/

Kim Jong-jae, Director of Asan Institute for Life Sciences and Head of Korea Data and Software-driven Healthcare Consortium which develops Dr. Answer. The Dr. Answer is a suite of AI-powered precision diagnostic software that supports healthcare. The suite is comprised of 21 AI-based software programs that assist diagnosis of 8 major diseases selected in consideration of mortality, the proportion of medical costs and public interest. Medical organizations verified its stability and effectiveness in improving accuracy in diagnosis and reducing diagnosing time. Recognizing the excellence of Dr. Answer, hospitals affiliated with the Ministry of National Guard-Health Affairs of Saudi Arabia are currently conducting its clinical verification while discussing the possibility of its adoption. (Photo: Business Wire)

Kim Jong-jae, Director of Asan Institute for Life Sciences and Head of Korea Data and Software-driven Healthcare Consortium which develops Dr. Answer. The Dr. Answer is a suite of AI-powered precision diagnostic software that supports healthcare. The suite is comprised of 21 AI-based software programs that assist diagnosis of 8 major diseases selected in consideration of mortality, the proportion of medical costs and public interest. Medical organizations verified its stability and effectiveness in improving accuracy in diagnosis and reducing diagnosing time. Recognizing the excellence of Dr. Answer, hospitals affiliated with the Ministry of National Guard-Health Affairs of Saudi Arabia are currently conducting its clinical verification while discussing the possibility of its adoption. (Photo: Business Wire)

Dr. Answer is a suite of AI-powered precision diagnostic software that supports healthcare. The suite is comprised of 21 AI-based software programs that assist diagnosis of 8 major diseases selected in consideration of mortality, the proportion of medical costs and public interest.

26 medical organizations developed Dr. Answer in collaboration with 22 information and communication technology companies in Korea for three years, and 38 medical organizations verified its stability and effectiveness in improving accuracy in diagnosis and reducing diagnosing time.

“Healthcare professionals at large general hospitals can easily make reference to opinions of other professionals when they involve in diagnosis and therapeutic decisions as a large number of professionals in diverse disciplines are working within the same hospitals. But a few medical professionals diagnose patients in many small hospitals or clinics where Dr. Answer can help professionals make an accurate diagnosis,” explained Kim Jong-jae, Director of Asan Institute for Life Sciences. “Dr. Answer can be usefully used in Europe, and countries with insufficient medical professionals such as Africa may achieve substantial outcomes when they use Dr. Answer,” added Kim.

Recognizing the excellence of Dr. Answer, hospitals affiliated with the Ministry of National Guard-Health Affairs of Saudi Arabia are currently conducting its clinical verification while discussing the possibility of its adoption.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005568/en/

CONTACT

Dr. Answer

Lee Junyoung

+82-43-931-5500

leejy@nipa.kr

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™